Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a pioneering biotechnology company focused on discovering and developing novel medicines aimed at targeting cancer vulnerabilities. Founded in 2017 with an initial $55 million Series A investment from Third Rock Ventures, Tango leverages the latest advancements in DNA sequencing and CRISPR-based target discovery. Their goal is to create breakthrough medicines that offer deeper and more sustained benefits than current targeted therapies and to extend the effectiveness of available immuno-oncology agents.
Tango Therapeutics concentrates on three core areas of drug development, each addressing well-defined patient populations with limited treatment options. These areas include:
- Loss of tumor suppressor gene function
- Multiple oncogenic drivers
- Immune evasion
The company’s robust product pipeline includes several promising candidates:
- TNG908 - An MTA-cooperative inhibitor of PRMT5 designed to selectively target cancer cells with MTAP deletions.
- TNG462 - Another advanced preclinical candidate aimed at targeting different cancer types.
- TNG348 - Recently entered Phase 1/2 clinical trials for advanced ovarian, breast, and other cancers with DNA damage repair pathway defects.
- Other discovery programs such as TNG260 and TNG348, focusing on different cancer types with limited current treatment options.
In recent developments, Tango announced dosing the first patient in the TNG348 Phase 1/2 trial, a significant milestone for the company. The trial will assess the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG348 both as a single agent and in combination with olaparib, a PARP inhibitor.
Tango has established partnerships with several key players in the pharmaceutical industry. These collaborations have significantly bolstered their drug development pipeline. However, recent news highlights the termination of the TNG348 Phase 1/2 clinical trial due to observed toxicity, underscoring the inherent risks in drug development.
For more information, visit www.tangotx.com.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in two upcoming investor conferences. Barbara Weber, M.D., President and CEO of Tango Therapeutics, will represent the company at these events:
1. 2024 Wells Fargo Healthcare Conference on September 4, 2024, at 12:45 PM ET in Boston, MA.
2. 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 AM ET in New York, NY.
Live webcasts of the presentations will be available on the company's website under the 'Events & Presentations' tab on the 'Investors' page. Replays will be archived for 90 days following each presentation.
Tango Therapeutics (NASDAQ: TNGX) reported Q2 2024 financial results and business highlights. Key points include:
1. Ongoing dose expansion in TNG908 and TNG462 phase 1/2 clinical trials, with a comprehensive PRMT5 program update expected in 2H 2024.
2. TNG260 phase 1/2 clinical trial patient enrollment continues.
3. Strong cash position of $322.1 million as of June 30, 2024, with runway into 2027.
4. Q2 2024 financial results: Collaboration revenue $7.8 million, license revenue $12.1 million, R&D expenses $38.7 million, G&A expenses $10.8 million, net loss $25.6 million ($0.24 per share).
5. Gilead licensed a drug discovery program for a $12.0 million fee in June.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotech company specializing in precision cancer medicines, announced that CEO Barbara Weber, M.D., will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:40 PM ET. The presentation will be webcast live on the company's website under the 'Events & Presentations' tab on the 'Investors' page, and a replay will be available for 90 days post-event.
Medivir announced that its licensee, Tango Therapeutics, has discontinued the clinical development of TNG348, a USP1 inhibitor aimed at treating BRCA1/2-mutant and HRD+ cancers, due to toxicity observed in phase 1/2 trials. The program was initially licensed from Medivir in 2020. Despite this setback, Medivir emphasized it remains focused on its lead program, fostroxacitabine bralpamide (fostrox), targeting primary liver cancer. The company is accelerating activities to initiate a pivotal phase 2b study for fostrox, which has the potential to secure market approval for treating HCC patients who fail current first-line treatments, a market projected to be worth $2.5 billion annually by 2028.
Tango Therapeutics (NASDAQ: TNGX) has discontinued its TNG348 program following Phase 1/2 trial results indicating liver toxicity in patients. The company emphasizes patient safety as the primary reason for halting the development of TNG348, a USP1 inhibitor. This decision will allow Tango Therapeutics to redirect resources toward its PRMT5 and CoREST clinical programs, which remain on track. The company has extended its cash runway into 2027 and plans to provide a comprehensive clinical update on TNG908 and TNG462 in the latter half of the year.
Tango Therapeutics, Inc. (NASDAQ: TNGX) reported strong financial results for Q1 2024 with a cash position of $344 million. The company is progressing its clinical programs, including dose expansion in TNG908 and TNG462 trials, with clinical data expected in 2H 2024. Tango is well-funded through late 2026. The company welcomed Julie Carretero as Chief Human Resources Officer to support growth.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
What is the core focus of Tango Therapeutics?
When was Tango Therapeutics founded?
What are some of the key products in Tango Therapeutics' pipeline?
What recent milestone did Tango Therapeutics achieve?
What happened to the TNG348 clinical trial?
What technologies does Tango Therapeutics leverage in their drug development?
Who are some of Tango Therapeutics' significant partners?
What makes Tango Therapeutics' approach unique?
Where can I find more information about Tango Therapeutics?
What are the risks associated with Tango Therapeutics' drug development?
